206 related articles for article (PubMed ID: 35613883)
1. Antisense modulation of IL7R splicing to control sIL7R expression in human CD4
Galarza-Muñoz G; Kennedy-Boone D; Schott G; Bradrick SS; Garcia-Blanco MA
RNA; 2022 Aug; 28(8):1058-1073. PubMed ID: 35613883
[TBL] [Abstract][Full Text] [Related]
2. Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk.
Galarza-Muñoz G; Briggs FBS; Evsyukova I; Schott-Lerner G; Kennedy EM; Nyanhete T; Wang L; Bergamaschi L; Widen SG; Tomaras GD; Ko DC; Bradrick SS; Barcellos LF; Gregory SG; Garcia-Blanco MA
Cell; 2017 Mar; 169(1):72-84.e13. PubMed ID: 28340352
[TBL] [Abstract][Full Text] [Related]
3. U2AF2 binds IL7R exon 6 ectopically and represses its inclusion.
Schott G; Galarza-Muñoz G; Trevino N; Chen X; Weirauch M; Gregory SG; Bradrick SS; Garcia-Blanco MA
RNA; 2021 Feb; 27(5):571-83. PubMed ID: 33568552
[TBL] [Abstract][Full Text] [Related]
4. Cleavage and polyadenylation specificity factor 1 (CPSF1) regulates alternative splicing of interleukin 7 receptor (IL7R) exon 6.
Evsyukova I; Bradrick SS; Gregory SG; Garcia-Blanco MA
RNA; 2013 Jan; 19(1):103-15. PubMed ID: 23151878
[TBL] [Abstract][Full Text] [Related]
5. Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis.
Sombekke MH; van der Voort LF; Kragt JJ; Nielsen JM; Guzel H; Visser A; Oudejans CB; Crusius JB; Peña AS; Vrenken H; Polman CH; Killestein J
Mult Scler; 2011 Aug; 17(8):922-30. PubMed ID: 21543551
[TBL] [Abstract][Full Text] [Related]
6. Context-specific regulation of surface and soluble IL7R expression by an autoimmune risk allele.
Al-Mossawi H; Yager N; Taylor CA; Lau E; Danielli S; de Wit J; Gilchrist J; Nassiri I; Mahe EA; Lee W; Rizvi L; Makino S; Cheeseman J; Neville M; Knight JC; Bowness P; Fairfax BP
Nat Commun; 2019 Oct; 10(1):4575. PubMed ID: 31594933
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 7 receptor polymorphisms and the risk of multiple sclerosis: A meta-analysis.
Tavakolpour S
Mult Scler Relat Disord; 2016 Jul; 8():66-73. PubMed ID: 27456877
[TBL] [Abstract][Full Text] [Related]
8. Antisense-mediated exon inclusion.
Hua Y; Krainer AR
Methods Mol Biol; 2012; 867():307-23. PubMed ID: 22454070
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the regulatory effects of synthesized antisense oligonucleotides on androgen receptor (AR) exon 3 splicing in prostate cancer cells.
Wang L; Gong S; Zhang X; Azhar Z; Chen J
Gene; 2023 May; 866():147330. PubMed ID: 36871670
[TBL] [Abstract][Full Text] [Related]
10. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity.
Lundström W; Highfill S; Walsh ST; Beq S; Morse E; Kockum I; Alfredsson L; Olsson T; Hillert J; Mackall CL
Proc Natl Acad Sci U S A; 2013 May; 110(19):E1761-70. PubMed ID: 23610432
[TBL] [Abstract][Full Text] [Related]
11. Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.
Scharner J; Ma WK; Zhang Q; Lin KT; Rigo F; Bennett CF; Krainer AR
Nucleic Acids Res; 2020 Jan; 48(2):802-816. PubMed ID: 31802121
[TBL] [Abstract][Full Text] [Related]
12. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice.
Hua Y; Vickers TA; Okunola HL; Bennett CF; Krainer AR
Am J Hum Genet; 2008 Apr; 82(4):834-48. PubMed ID: 18371932
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon.
Hua Y; Vickers TA; Baker BF; Bennett CF; Krainer AR
PLoS Biol; 2007 Apr; 5(4):e73. PubMed ID: 17355180
[TBL] [Abstract][Full Text] [Related]
15. Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing.
Karras JG; McKay RA; Dean NM; Monia BP
Mol Pharmacol; 2000 Aug; 58(2):380-7. PubMed ID: 10908306
[TBL] [Abstract][Full Text] [Related]
16. High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed
Wijaya YOS; Niba ETE; Nishio H; Okamoto K; Awano H; Saito T; Takeshima Y; Shinohara M
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456491
[TBL] [Abstract][Full Text] [Related]
17. Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing.
Putscher E; Hecker M; Fitzner B; Boxberger N; Schwartz M; Koczan D; Lorenz P; Zettl UK
Front Immunol; 2022; 13():931831. PubMed ID: 36405756
[TBL] [Abstract][Full Text] [Related]
18. Consensus Guidelines for the Design and
Aartsma-Rus A; Garanto A; van Roon-Mom W; McConnell EM; Suslovitch V; Yan WX; Watts JK; Yu TW
Nucleic Acid Ther; 2023 Jan; 33(1):17-25. PubMed ID: 36516128
[TBL] [Abstract][Full Text] [Related]
19. Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides.
Wang Z; Jeon HY; Rigo F; Bennett CF; Krainer AR
Open Biol; 2012 Oct; 2(10):120133. PubMed ID: 23155487
[TBL] [Abstract][Full Text] [Related]
20. Association analysis of IL7R polymorphisms with inflammatory demyelinating diseases.
Kim JY; Cheong HS; Kim HJ; Kim LH; Namgoong S; Shin HD
Mol Med Rep; 2014 Feb; 9(2):737-43. PubMed ID: 24337176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
